Universität zu Köln

Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara and Hallek, Michael (2019). Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in Real-Life Outside of Clinical Trials. Anticancer Res., 39 (5). S. 2591 - 2599. ATHENS: INT INST ANTICANCER RESEARCH. ISSN 1791-7530

Full text not available from this repository.

Abstract

Background: Only few studies have focused exclusively on patients with small lymphocytic lymphoma (SLL). Patients and Methods: In the present report, 103 SLL patients were analyzed from both, clinical trials of the German Chronic Lymphocytic Leukemia Study Group and Greek centers, and emphasis was placed on the therapeutic strategy. The impact of lymph node characteristics, such as the presence of proliferation centers (PCs) on response and survival was also assessed. Results: SLL patients included in clinical trials were treated mostly with fludarabine-based regimens while those in reallife were staged and treated mostly as patients with low-grade lymphomas. Our analysis showed a trend for better survival for patients with SLL without detectable PCs. Conclusion: Patients with SLL outside of clinical trials are usually treated as cases of lymphoma. In addition, this analysis supports published data regarding the adverse prognostic value of the presence of PCs in lymphoid nodes in SLL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sachanas, Sotirios UNSPECIFIED UNSPECIFIED UNSPECIFIED Pangalis, Gerassimos A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fink, Anna-Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Bahlo, Jasmin UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Levidou, Georgia UNSPECIFIED UNSPECIFIED UNSPECIFIED Kyrtsonis, Marie-Christine UNSPECIFIED UNSPECIFIED UNSPECIFIED Bartzi, Vassiliki UNSPECIFIED UNSPECIFIED UNSPECIFIED Vassilakopoulos, Theodoros P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kalpadakis, Christina UNSPECIFIED UNSPECIFIED UNSPECIFIED Koulieris, Efstathios UNSPECIFIED UNSPECIFIED UNSPECIFIED Moschogiannis, Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Yiakoumis, Xanthi UNSPECIFIED UNSPECIFIED UNSPECIFIED Tsirkinidis, Pantelis UNSPECIFIED UNSPECIFIED UNSPECIFIED Angelopoulou, Maria K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-149175
DOI:	10.21873/anticanres.13382
Journal or Publication Title:	Anticancer Res.
Volume:	39
Number:	5
Page Range:	S. 2591 - 2599
Date:	2019
Publisher:	INT INST ANTICANCER RESEARCH
Place of Publication:	ATHENS
ISSN:	1791-7530
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROLIFERATION CENTERS; CYCLOPHOSPHAMIDE; CLASSIFICATION; FLUDARABINE; RITUXIMAB Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14917